These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33202219)

  • 1. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
    Silvain J; Lattuca B; Beygui F; Rangé G; Motovska Z; Dillinger JG; Boueri Z; Brunel P; Lhermusier T; Pouillot C; Larrieu-Ardilouze E; Boccara F; Labeque JN; Guedeney P; El Kasty M; Laredo M; Dumaine R; Ducrocq G; Collet JP; Cayla G; Blanchart K; Kala P; Vicaut E; Montalescot G;
    Lancet; 2020 Nov; 396(10264):1737-1744. PubMed ID: 33202219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
    Silvain J; Cayla G; Beygui F; Range G; Lattuca B; Collet JP; Dillinger JG; Boueri Z; Brunel P; Pouillot C; Boccara F; Christiaens L; Labeque JN; Lhermusier T; Georges JL; Bellemain-Appaix A; Le Breton H; Hauguel-Moreau M; Saint-Etienne C; Caussin C; Jourda F; Motovska Z; Guedeney P; El Kasty M; Laredo M; Dumaine R; Ducrocq G; Vicaut E; Montalescot G;
    Am Heart J; 2020 Jul; 225():27-37. PubMed ID: 32473356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome.
    Manzo-Silberman S; Guedeney P; Cayla G; Beygui F; Rangé G; Motovska Z; Procopi N; Kerneis M; Zeitouni M; El Kasty M; Teiger E; Filippi E; Coste P; Huchet F; Cottin Y; Karasek J; Arnould MA; Braik N; Barthelemy O; Portal JJ; Vicaut E; Montalescot G; Silvain J;
    JACC Cardiovasc Interv; 2024 Jun; 17(12):1413-1421. PubMed ID: 38842993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2Y
    Roule V; Beygui F; Cayla G; Rangé G; Motovska Z; Delarche N; Jourda F; Goube P; Guedeney P; Zeitouni M; El Kasty M; Laredo M; Dumaine R; Ducrocq G; Derimay F; Van Belle E; Manigold T; Cador R; Combaret N; Vicaut E; Montalescot G; Silvain J;
    Can J Cardiol; 2024 Jan; 40(1):31-39. PubMed ID: 37660934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome.
    Lattuca B; Mazeau C; Cayla G; Ducrocq G; Guedeney P; Laredo M; Dumaine R; El Kasty M; Kala P; Nejjari M; Hlinomaz O; Morel O; Varenne O; Leclercq F; Payot L; Spaulding C; Beygui F; Rangé G; Motovska Z; Portal JJ; Vicaut E; Collet JP; Montalescot G; Silvain J;
    JACC Cardiovasc Interv; 2024 Feb; 17(3):359-370. PubMed ID: 38355265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
    Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
    Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ;
    Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
    Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
    Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
    Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
    J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes.
    Liu Z; Tian R; Wang Y; Chen Q; Li J; Xu L; Zhang S
    Thromb Haemost; 2020 Aug; 120(8):1221-1229. PubMed ID: 32668483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
    Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry.
    Völz S; Petursson P; Odenstedt J; Ioanes D; Haraldsson I; Angerås O; Dworeck C; Hirlekar G; Myredal A; Albertsson P; Råmunddal T; Redfors B; Omerovic E
    J Am Heart Assoc; 2020 Jul; 9(14):e015990. PubMed ID: 32662350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
    Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
    Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.